 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
About NanoCor NanoCor Therapeutics, Inc. is a biotechnology company focused on developing novel molecular therapies for patients with cardiovascular disease. About Chronic Heart Failure What is Congestive Heart Failure? |
|||||||
 |
Research and Development Carfostin™ |
||||||
 |
Technology Biological Nanoparticle (BNPs™) Technology Self-complimentary vector technologies |
||||||
 |
For Investors Investor Resources, Market Opportunity, etc |
||||||
 |
Spotlight on CHF Chronic heart failure overview, statistics and progress |
||||||
NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.